Patients with EBV-positive B- and T/NK-cell lymphoma or lymphoproliferative disorder were administered donor-derived T cells specific for the EBV LMP proteins following allogeneic HSCT, either as adjuvant therapy or as treatment of relapsed disease. The OS of patients receiving T cells as adjuvant therapy was 78%, supporting the infusion of LMP-Ts to improve the outcome of patients in this setting. CI, confidence interval. The figure has been adapted from Figure 7B in the article by McLaughlin et al that begins on page 2351.